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ihe 11th Annual Scientific session of the American Society
uclear Cardiology (ASNC, chaired by Dr. Daniel Berman)
as held from September 7 through 10, 2006, in Montreal,
anada, with more than 1,100 registrants in attendance. This
-day meeting was divided into 4 major tracks (plenary
essions, core curriculum, advanced track, and investigative
rack) as well as read-with-the-expert sessions and satellite
ymposia. In addition, original research was contributed in
he form of abstract presentations and included a competi-
ion in the Young Investigator Award.
lenary Sessions
he Mario Verani Memorial Lecture: evolving chal-
enges and opportunities for nuclear cardiology (Dr. Ami
skandrian) The Mario Verani lecture is presented each
ear at the ASNC annual meeting by a prominent nuclear
ardiologist in memory of Dr. Mario Verani (1943 to 2001),
pioneer in nuclear cardiology and founder and past-
rom the *Leiden University Medical Center, Leiden, the Netherlands; †Brown
edical School, Providence, Rhode Island; ‡University of Ottawa Heart Institute,
ttawa, Canada; §Johns Hopkins University Medical Center, Baltimore, Maryland;
Cedars-Sinai Medical Center, Los Angeles, California; ¶Emory University School of
edicine, Atlanta, Georgia; #Midwest Heart Specialists, Chicago, Illinois; **NYU
edical Center, New York, New York; and ††Yale University Medical School, New
aven, Connecticut. Dr. Bax has received research grants from Guidant, Medtronic,
E Healthcare, and BMS Medical Imaging; Dr. Beanlands has received research
rants from GE Healthcare and MSD Nordion and is on the advisory board of BMS
edical Imaging; Dr. Berman has received research grants from BMS Medical
maging and Astellas Pharma US, Inc., and is a consultant at Mallinckrodt; Dr.
arcia has received research grants from Bracco Diagnostics Inc., BMS Medical
maging, and GE Healthcare and is on the speakers bureau for GE Healthcare; he
lso has received an honoraria from GE Healthcare; Dr. Hendel has received research
rants from GE Healthcare and is on the advisory bureau of BMS Medical Imaging;
r. Mieres has received research grants from GE Healthcare and is on the speakers
ureau for Astellas Pharma US, Inc.; Dr. Shaw has received research grants from GE
ealthcare and is on the speakers bureau at GE Healthcare; and Dr. Wackers has
eceived research grants from BMS Medical Imaging, Astellas Pharma US, Inc., and
E Healthcare; royalties from MedX, WLCQ software; and is on the advisory boardo
f King Pharmaceuticals.
Manuscript received November 3, 2006; accepted November 7, 2006.resident of ASNC. In the fifth Mario Verani Lecture,
r. Iskandrian addressed new challenges and opportuni-
ies for nuclear cardiology. He noted that although Amer-
can Heart Association/American College of Cardiology
uidelines recognize many class 1 indications for radio-
uclide imaging, there is a paucity of evidence-based
Level 1) data. Prospective multicenter trials, such as the
NSPIRE (AdenosINe Sestamibi Post-InfaRction Eval-
ation) trial, that use radionuclide imaging end points are
uch needed.
Dr. Iskandrian also discussed the use of radionuclide
maging for defining end points of novel therapies, such as
egenerative therapy with stem cells. He emphasized the
mportance of quantification of myocardial perfusion and/or
unction, especially in view of the substantial interobserver
ariability even among expert readers using visual analysis.
ccordingly, the Food and Drug Administration has now
ccepted quantitative image analysis as an alternative for
ultiple readers’ visual interpretation.
Another technique discussed by Dr. Iskandrian is neuro-
al imaging with 123I-metaiodobenzylguanidine (MIBG).
everal multicenter studies are now underway using
IBG single-photon emission computed tomography
SPECT) to explore which patients are at risk for sudden
ardiac death and which benefit from implantable
ardioverter-defibrillator therapy. The role of imaging in
pecial populations, including those with chronic kidney
isease, also was highlighted. Forty-seven percent of
hese patients die from cardiovascular complications.
owever, even after coronary revascularization, survival
emains poor. Moreover, many patients die with normal
eft ventricular (LV) ejection fraction, and patients with
ormal myocardial perfusion have worse outcome as
ompared with the normal population. Thus, unresolved
ssues remain in patient management, including the use
f radionuclide imaging in renal dysfunction.
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January 30, 2007:502–8 Highlights of 2006 ASNC Scientific Sessionsetecting the high-risk patient. Dr. William Wijns dis-
ussed the clinical value of radionuclide imaging and com-
uted tomographic (CT) angiography in detection of the
igh-risk patient. In the past, visualization of the coronary
rteries was the domain of invasive angiography and the
hreshold for angiography was relatively high. Myocardial
erfusion imaging served efficiently as the gatekeeper to this
nvasive procedure. However, with the recent introduction
f noninvasive CT angiography, the threshold has become
onsiderably lower, and low-risk patients may have their
oronary anatomy visualized. This development resulted in
etection of coronary artery disease (CAD) at an earlier
tage with more mild and nonobstructive CAD detected
han before. To better understand the clinical significance of
hese findings and decide on appropriate clinical manage-
ent, new demands and questions are put on myocardial
erfusion imaging. For example, in a study of 140 patients
ith intermediate likelihood of CAD who all had multislice
T angiography, no CAD was found in approximately
ne-third of patients, nonobstructive CAD in another
ne-third, and obstructive CAD (50% luminal narrowing)
n another one-third of patients. However, 40% of patients
ith nonobstructive CAD had abnormal perfusion on stress
PECT, and 50% of patients with obstructive CAD had
ormal perfusion on stress SPECT.
Invasive tools used during cardiac catheterization to
valuate coronary flow reserve and, thus, the entire coronary
rterial system, demonstrate a substantial spread and overlap
f coronary flow reserve in patients with obstructive and
onobstructive CAD, suggesting that many of the appar-
ntly false-positive stress SPECT studies may be due to
bnormal coronary flow reserve. Conversely, patients with
alse-negative stress SPECT studies may have adequate collat-
ral circulation. Invasive interrogation of the coronary flow
eserve clearly demonstrates the limitations of coronary anat-
my as visualized by either invasive or noninvasive coronary
ngiography. The prior experience with invasive angiogra-
hy now needs to be translated into noninvasive cardiac
maging techniques to aid physicians in making appropriate
linical decisions. Noninvasive imaging also may aid coro-
ary angiography in patient populations that are at higher
isk, but who are still underdiagnosed and undertreated,
uch as patients with diabetes, women, and the elderly. Dr.
ijns concluded that noninvasive cardiac imaging is well
ositioned to play an important role to guide therapy in the
igh-risk patient. More than ever, there is a need for
ccurate evaluation of the hemodynamic significance of
ndividual coronary stenoses. The knowledge derived from
nvasive evaluation of vulnerable, non–flow-limiting plaques
eeds to be transferred to noninvasive imaging. This re-
uires “crosstalk” between interventional cardiologists and
oninvasive cardiac imagers. Ultimately, the incremental
ost-effectiveness of diagnostic imaging procedures will have
o be demonstrated.
uclear imaging in special populations. Dr. Avjit Lahiriointed out that, by the year 2030, the number of patients fith type 2 diabetes mellitus
orldwide will amount to 370
illion. The risk for developing
AD is 2- to 4-fold higher in
atients with diabetes than in
ondiabetic patients, and in
any patients with diabetes,
AD is asymptomatic. Stress
yocardial perfusion imaging
as been shown to be equally
ffective in detecting the pres-
nce of CAD and in estimating
rognosis as in patients without
iabetes. However, for any given
ize of myocardial perfusion ab-
ormality, the mortality in pa-
ients with diabetes was 2-fold
reater. In addition, the long-
erm outcome in patients with
iabetes and normal SPECT im-
ges was 1.5- to 3-fold worse
han patients without diabetes.
everal studies assessed the prev-
lence of silent CAD in truly asymptomatic patients with
iabetes. Dr. Lahiri proposed the use of CT coronary
alcium scoring (CAC) as a prescreening tool to enrich the
arget population. If only diabetic patients with CAC 100
gatston units would be screened with stress SPECT
maging, approximately 50% of patients can be anticipated
o have abnormal SPECT images, with 20% being markedly
bnormal, far greater than noted when examining all asymp-
omatic diabetics. The use of CAC scoring and stress
yocardial SPECT are therefore synergistic in predicting
ardiovascular mortality and morbidity and may prove to be
cost-effective approach in asymptomatic patients with
iabetes.
alue of radionuclide imaging in patients with heart
ailure. Dr. Prem Soman discussed the value of radionu-
lide imaging in patients with heart failure. Myocardial
erfusion imaging has been used extensively in patients with
eart failure for the detection of CAD (to differentiate
etween ischemic and nonischemic cardiomyopathy), in the
ssessment of myocardial viability, for risk stratification, and
n the quantification of LV (dys)function. Radionuclide
maging has been useful in the identification of the 70% of
atients with ischemic cardiomyopathy, ischemic, and/or
ysfunctional but viable myocardium who can benefit from
evascularization with improvement in symptoms, regional
nd global LV function, and survival.
The use of neurohumoral imaging with MIBG predicts
utcome in both ischemic and nonischemic cardiomyopathy
nd may be used to monitor response to heart failure
herapy. Dr. Leslee Shaw also addressed the role of nuclear
maging in women. Before the introduction of contempo-
ary techniques, myocardial perfusion imaging was notable
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CT  computed
tomography
FDG 
18F-fluorodeoxyglucose
LV  left ventricular
MIBG 
123I-metaiodobenzylguanidine
MMP  matrix
metalloproteinase
MRI  magnetic resonance
imaging
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomographyor a lower diagnostic accuracy in women than in men
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Highlights of 2006 ASNC Scientific Sessions January 30, 2007:502–8ecause of technical issues (e.g., breast attenuation) but also
athophysiological issues (e.g., women more often have
mall vessel disease and more nonobstructive CAD). Recent
dvances in SPECT imaging, including the use of attenu-
tion correction and prone imaging, have significantly
mproved diagnostic accuracy in women.
ore Curriculum:
dvances in Nuclear Cardiology
uantitative analysis. The visual assessment of scinti-
raphic images remains problematic because of attenuation
rtifacts, poor interobserver agreement, and lack of precise
uantification of defect extent and severity. With the
urrently available software programs, accurate and repro-
ucible quantitative analysis is possible, not only for assess-
ent of myocardial perfusion and function but also for
valuation of tracer lung uptake, transient ischemic dilation,
V shape and eccentricity, and LV mass. Drs. Ernest
arcia and Guido Germano discussed recent advancements
n the field of quantification, including phase analysis
evaluating LV systolic dyssynchrony) and the assessment of
iastolic function (by defining the derivative of the time-
olume curve to estimate peak filling rates).
yocardial perfusion imaging with positron emission
omography (PET). In clinical cardiology, PET has
een used mainly for viability assessment with 18F-
uorodeoxyglucose (FDG) imaging, but recent studies have
eported on the use of PET perfusion imaging to detect and
valuate CAD, noting the improved image quality with
ET as compared with SPECT imaging. Dr. Timothy
ateman explained that the advantages of PET include
mproved spatial and contrast resolution, greater count
ensity, improved scatter counts, and the automatic use of
ttenuation correction algorithms. Particularly in patients
ith a nondiagnostic SPECT study, these technical advan-
ages of PET assist in disease evaluation and also offer the
otential to provide absolute quantification of myocardial
erfusion, which contributes to more accurate detection of
AD, particularly in patients with multivessel CAD. In
hese patients, a SPECT study may be normal because a
alanced reduction in myocardial perfusion will be present;
bsolute quantification, however, will note the balanced reduc-
ion in the different coronary territories. Also, a PET perfusion
tudy can be completed in 20 min, which may allow higher
atient throughput. Finally, there is now growing evidence on
he prognostic value of PET perfusion studies, showing similar
bilities for risk stratification as with SPECT.
Dr. Marcelo Di Carli discussed the expanding role of
ybrid PET-CT imaging. Anatomical information on cor-
nary artery anatomy and extent of atherosclerosis, as well as
unctional information regarding ischemia and perfusion,
an be obtained and combined together in a “fused” image.
arious studies have shown that CT angiography has an
xtremely high negative predictive value, indicating that a
ormal CT angiogram virtually excludes CAD. Conversely, en the presence of atherosclerosis on CT angiography, the
ET perfusion information may indicate the hemodynamic
ignificance of the lesions. Whether this integrated infor-
ation provides superior prognostic information remains to
e shown, although clearly this technique has great promise.
dvanced Clinical Track:
erits of Different Imaging Modalities
maging to evaluate coronary plaques. The detection of
ctive plaques at risk of rupture would allow the identifica-
ion of vulnerable patients. Dr. Mari Aparici highlighted
he value of nuclear imaging to target specific molecular and
ellular processes of the vulnerable plaque. Radiolabeled
gents to detect a vulnerable plaque imaging target several
spects of the atherosclerotic process, include inflammation
using FDG uptake by macrophages and monocytes), apo-
tosis (using 99mTc-labeled annexin-V), matrix metallopro-
einase activity (using labeled matrix metalloproteinases
MMPs]), proliferating vascular endothelial and smooth
uscle cells (using 111In-Z2D3 and labeled v3 integrins).
reliminary data in carotid arteries suggest that the best
esults are currently obtained with annexin-V and FDG,
hich provide high contrast between lesions and normal
essels. Additionally, diffuse inflammation can be identified
n FDG-PET. However, the process of vascular inflamma-
ion is not stable over time, and FDG uptake may vary.
alcification of lesions may be caused by apoptosis and,
herefore, some researchers have suggested that annexin-V
ay become a better indicator. Dr. William Strauss pointed
ut that precise localization of the disease activity (as
etected by nuclear imaging) may be difficult, but hybrid
ystems such as PET-CT and SPECT-CT may permit
laque imaging with accurate anatomical co-registration.
Dr. Zahi Fayad addressed the role of magnetic resonance
maging (MRI) for the evaluation of plaque composition.
ecent studies using 3-T MRI have indeed shown superior
valuation of plaque composition and visualization of plaque
emorrhage. Another potential of MRI is the combination
ith intravascular probes for plaque evaluation and
isualization.
Dr. William Wijns addressed the value of invasive imag-
ng techniques. Recent developments include improved
valuation of plaque composition with intravascular ultra-
ound using virtual histology analysis. Very precise quanti-
cation of plaque volume and components is possible with
ptical coherence tomography. These newer invasive imag-
ng techniques may have the potential to distinguish be-
ween stable and unstable atherosclerotic plaques.
maging to evaluate therapy. During recent years, large
atabases examining risk stratification with (gated) SPECT
erfusion imaging have been published, and perfusion
maging is now used frequently as an end point to evaluate
nd compare therapies, as discussed by Drs. Leslee Shaw
nd John Mahmarian. These trials range from small studies
valuating novel revascularization or regenerative therapies,
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January 30, 2007:502–8 Highlights of 2006 ASNC Scientific Sessionso large randomized, controlled trials evaluating global
anagement or comparisons between different testing strat-
gies. Evaluations of novel therapies include laser revas-
ularization, gene therapy, and stem cell therapy. Exam-
les of large studies evaluating global management are
he INSPIRE trial, the ACME (Angioplasty Compared to
edical Therapy) trial, and the COURAGE (Clinical
utcomes Using Revascularization and Aggressive Drug
valuation) trial. In these trials, the relative effects of
evascularization and drug therapy on ischemia were evalu-
ted using myocardial perfusion imaging. The DIAD (De-
ection of Ischemia in Asymptomatic Diabetics) trial is an
xample of a comparison of different testing strategies:
symptomatic diabetic patients undergo risk stratification
ased on routine clinical work-up or with the inclusion of
yocardial perfusion imaging (to assess ischemia). Finally,
ecause the reproducibility of (gated) SPECT is high,
erfusion imaging is ideal for serial monitoring of effect of
ifferent medical therapies, and improvement in perfusion
as been demonstrated after beta-blockers, statins, and
ngiotensin-converting enzyme inhibitors.
Drs. Paolo Raggi and Zahi Fayad discussed the potential
oles of electron beam CT and MRI to evaluate progression
r regression of atherosclerosis. Both techniques appear
romising for sequential imaging, whereas multislice CT
because of the high radiation dose) at present is not suited
or sequential imaging.
maging in heart failure. Different imaging modalities
ften provide complementary information in patients with
eart failure. Radionuclide imaging continues to provide key
linical information on LV function, ischemia, and hiber-
ation, which are important in therapeutic decision making
or the patient with heart failure. More work is needed to
nderstand the desired outcomes in patients with heart
ailure because it is clear that the improvement in LV
unction after revascularization does not always translate
nto better outcome. In addition, interest in autonomic
ervous system imaging is increasing, and the role of
IBG imaging to predict outcome in patients with heart
ailure is being evaluated in a multicenter study. Dr.
ames Fallavolita noted that hibernating myocardium is
ssociated with partial denervation, as evidenced by
educed 11C-hydroxyephrine uptake on PET, which may
ndicate high risk for sudden cardiac death.
New echo techniques also are important in evaluation of
atients with heart failure; particularly, 3-dimensional echo-
ardiography may provide optimal information on LV
unction and shape in addition to the presence/etiology of
itral regurgitation. A very important issue is selection for
ardiac resynchronization therapy, which is mainly based on
ssessment of LV dyssynchrony. At present, echocardiog-
aphy using tissue Doppler imaging and strain (rate) imag-
ng appears well suited for assessment of LV dyssynchrony.
The role of MRI in patients with heart failure is mainly
o assess LV function and, using contrast-enhanced imag-
ng, to precisely delineate the presence and extent of scar cissue/presence of viable myocardium. Dr. Chris Kramer
ndicated that, for optimal prediction of functional recovery
fter revascularization, the assessment of scar tissue (with
ontrast-enhanced MRI) should be combined with the
ssessment of contractile reserve (with low-dose dobut-
mine MRI).
dvanced Clinical Track:
pdate in Instrumentation
he principal hurdle in cardiac PET-CT is artifact caused
y transmission misalignment. This can be improved by
ating both cardiac and respiratory motion and is the focus
f current research. Technology improvements continue to
earch for new detector materials, improved design, and im-
roved resolution. Lutetium oxyorthosilicate and Bismuth-
ermanate currently have the highest density and highest
ffective Z coordinate, respectively, among the more widely
vailable detectors; however lutetium-yttrium oxyorthosili-
ate and Lanthanum bromide may provide high light output
nd stopping power. Time of flight will lead to increased
esolution that will improve lesion contrast. The true incre-
ental value of this for cardiac imaging remains to be seen but
ould become particularly important if plaque imaging be-
omes a clinical reality. From the CT aspect, the potential
dvantages of 64-slice CT need to be considered: 64-slice
ameras increase scan speed, which improves contrast reso-
ution and permits a shortened breath hold, which means,
or CT, a higher spatial resolution resulting in detailed
ascular mapping, more accurate measurement of coronary
rtery stenosis, and optimal 3D visualization. In the future,
ual-source CT (2 X-ray tubes rotating) may improve
emporal resolution and permit tissue characterization, es-
ecially at higher heart rates and reduce patient radiation
ose by imaging twice as fast.
With regard to SPECT imaging, attenuation correction
as been and remains available. Although recommended by
SNC, only few centers are actually using attenuation
orrection in SPECT imaging. An exciting development is
ew devices that may enable dynamic SPECT imaging,
ermitting absolute quantification of perfusion. New meth-
ds, such as motion frozen perfusion or “thin plate spline
arping,” may improve image quality by bringing images to
iastolic position.
nvestigative Track:
uclear Imaging and Basic Science
he investigative track comprised 3 sessions, which all were
edicated to advanced topics involving nuclear imaging
rimarily on a basic science level. The first session was
edicated to the role of genomics, proteomics, and imaging
n the pathway toward personalized medicine. Dr. Joseph
u summarized existing genomic techniques. Applications
f such gene-targeted approaches seem to get closer to the
linics, but costs associated with gene chips and subsequent
onfirmatory analyses are not negligible. Although genomic
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Highlights of 2006 ASNC Scientific Sessions January 30, 2007:502–8nalyses identify certain candidate genes associated with a
isease, it needs to be emphasized that the pure presence of
gene does not reflect its level of transcription and trans-
ation into a protein as the true effector molecule. Proteomic
nalysis is thus considered an important aspect of molecular
nalysis of disease, and proteomic techniques were outlined
y Dr. Anrzej Chruscinski. A variety of unbiased techniques
o identify previously unknown proteins associated with
isease conditions are available. The substantial challenge of
ntegrating genomics, proteomics, and imaging to achieve
he visionary goal of individualized health care was then
utlined by Dr. Frank Bengel. It was proposed that results
rom gene expression profiles, proteomic profiles, clinical
nformation, and imaging are being integrated into models
o predict individual diagnosis, risk, and therapy response.
maging can play a key role in this integrative process by
llowing for a precise description of the individual pheno-
ype. A consensus of the session was that despite the
ell-perceived complexity of the topic, the common vision-
ry goal of personalized medicine should stimulate increas-
ng interaction between imagers, clinicians and molecular
cientists.
The second session was dedicated to novel molecular
iagnostic approaches in heart failure and examined a
ariety of novel therapeutic approaches. Dr. Albert Sinusas
xplained the role of MMPs in the pathophysiology of LV
emodeling as a key feature of heart failure development and
rogression. Novel MMP ligands for SPECT imaging have
een introduced recently and provide robust signals from
nfarct and peri-infarct areas. Metabolic alterations as an-
ther critical component of LV dysfunction were reviewed
y Dr. Pablo Soto. Nuclear imaging with SPECT and PET
llows for identification of the relative utilization of glucose
nd fatty acids as substrates for energy consumption. As part
f the early disease process, shifts in substrate use may occur
ithin the cardiomyopathic heart, thereby contributing to
isease progression and decrease of contractile performance.
he role of receptor systems in heart failure is well known
nd has stimulated the development of several drugs used
or treatment. Dr. Frank Bengel emphasized that imaging
f postsynaptic receptors is a significant challenge for
uclear imaging. Imaging of presynaptic innervation itself
ay thus be a sufficiently accurate molecular approach to
haracterize involvement of the adrenergic nervous system
n heart failure progression. The session successfully dem-
nstrated that several very specific biologic imaging ap-
roaches are on the horizon that may allow for improved
tratification of patients with heart failure in the future.
The third session was dedicated to imaging as a tool to
rovide insights into vascular biology and disease. Dr.
lordeliza Villanueva outlined the potential of ultrasound
or targeted imaging of vascular structures. Microbubbles
an be used as contrast agents, which can be specifically
argeted toward intravascular molecules if the bubbles are
oupled with molecular ligands. An innovative strategy for
etection of the accumulation of small amounts of radionu- llides within the vessel wall could be the use of intravascular
robes. Dr. William Strauss outlined this novel strategy,
hich is based primarily on beta-particle sensitive scintilla-
ors incorporated in small intravascular catheters. These
atheters can even be combined with other techniques such
s intravascular thermography to measure inflammation.
inally, the role of targeted imaging of v3 integrin, an
dhesion molecule involved in angiogenesis, was high-
ighted. Dr. Albert Sinusas provided an overview of recently
vailable integrin-targeted SPECT tracers and their accu-
ulation in ischemically damaged tissue. Integrin expres-
ion occurs to some degree in atherosclerotic lesions but
ore so in graft arteriopathy, as outlined by Dr. Mehran
adeghi in the final talk of the session. Such novel tracers
nd techniques are thus expected to significantly improve
he understanding of vascular biology, and they may enter
he clinical arena as markers of disease outcome or therapy
esponse.
riginal Research: Abstract Contributions
total of 110 abstracts were selected from a group of
ompetitive submissions after peer review. All selected
bstracts were published in the July/August issue of the
ournal of Nuclear Cardiology. A brief synopsis of these
resentations is provided herein
oung investigator award. This symposium comprised 6
ral presentations focusing mainly on clinical aspects of
yocardial perfusion imaging. Somekh et al. (1) presented
esults of a comparative study of the performance of a
edicated chest pain unit, a hospitalist service, and a private
ttending service for handling patients with chest pain but
ithout an acute coronary syndrome. Strategies included
he usage of myocardial perfusion imaging, which was used
ost efficiently in the chest pain unit, where outcomes
eemed to be best. Shah et al. (2) analyzed the independent
redictors of outcome in elderly patients (age 75 years)
ndergoing myocardial perfusion-gated SPECT and ob-
erved that patients who were not able to exercise had
igher event rates, whereas perfusion abnormalities and LV
jection fraction were also independent predictors of out-
ome. Mehta et al. (3) won the young investigator award,
eporting on the clinical application of the American Col-
ege of Cardiology Foundation (ACCF)/ASNC appropri-
teness criteria for perfusion SPECT. These authors ob-
erved that 82% of the appropriately indicated studies were
ssociated with less normal results and more severe abnor-
alities on SPECT than in the inappropriate-indicated
tudies. Still, there were 31% abnormal studies in the
nappropriately referred group, a finding that requires fur-
her investigation. Mohmed et al. (4) presented a novel
-dimensional iterative algorithm for gated SPECT recon-
truction and observed excellent correlation with standard
ltered back-projection data. The setting was a high-count
tress study, and it was concluded that further tests in
ow-count studies are warranted.
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January 30, 2007:502–8 Highlights of 2006 ASNC Scientific SessionsDruz et al. (5) observed that discharge of implantable
ardioverter defibrillators was not associated with residual
schemia on gated SPECT but rather with ongoing LV
emodeling, as indicated by lower LV ejection fraction and
arger volumes. Finally, Moloo et al. (6) evaluated FDG
ptake as a marker of plaque inflammation in carotid
rteries of patients before endarterectomy. The authors
oncluded that significant FDG uptake occurred not only in
he artery scheduled for surgery but also in the contra-lateral
rtery, suggesting diffuse inflammatory atherosclerotic
isease.
ontemporary clinical contributions. Various abstracts
ere related to the diagnosis of CAD using SPECT
yocardial perfusion imaging. Both transient ischemic LV
avity dilation and tracer lung uptake after stress were
elated to severe CAD (7,8). Conversely, small poststress
V dimensions were related to less-extensive CAD (9).
nferior perfusion defects were considered to be related to
ess extensive ischemia (and generally invasive angiography
s not performed in these patients), but Kardan et al. (10)
emonstrated a high frequency (76%) of multivessel CAD
n angiography in patients with ischemia in the inferior wall
n SPECT.
Attenuation artifacts remain a problem with SPECT
maging, particularly with obese patients (11). Two studies
ndicated the superior diagnostic performance when X-ray
ttenuation correction was included (12,13). With the new
PECT-CT scanners, attenuation correction may become
mplemented in the daily routine (14), but Goetze et al. (15)
ointed out that misregistration between the 2 techniques is
ot infrequent and that re-registration is often needed (16).
Several studies compared CT angiography with SPECT
maging for assessment of CAD (17,18). Schepsis et al. (18)
emonstrated that the techniques provide complementary
nformation and integration of the 2 techniques may opti-
ize diagnosis of CAD. Fusion of the CT and SPECT
mages may be problematic, but algorithms to fuse these
mages are being developed (19).
Using gated SPECT, Oba et al. (20) compared regional
all motion abnormalities to those noted with MRI and
emonstrated good agreement between the 2 techniques,
ven in the presence of perfusion defects. The prognostic
se of SPECT imaging was confirmed in different subpopu-
ations, including the elderly (21) and patients undergoing
reoperative risk stratification before abdominal aortic an-
urysm surgery (22).
A retrospective analysis of 374 patients with atrial fibril-
ation, compared with age- and gender-matched controls
evealed a high incidence of perfusion abnormalities in both
roups, but the prognostic yield was not greater in patients
ith atrial fibrillation, suggesting that routine screening
ith SPECT may not be justified (23).
Also, the prognostic value of different variables derived
rom gated SPECT imaging was addressed. One study
emonstrated that patients with normal perfusion on stress
PECT study had an excellent prognosis, suggesting that in phese patients a resting study may be omitted (24). Wexler
t al. (25) demonstrated the incremental prognostic value of
V end-systolic volume over LV ejection fraction and
erfusion variables, most outspoken in women. Another
tudy reported on the prognostic value of reversible wall
otion abnormalities on gated SPECT, which most likely
epresents postischemic stunning and was associated with
oor outcome (26).
ET. Folks et al. (27) reported on the development of
ormal limits for perfusion imaging with PET and 82rubid-
um, whereas Goeke et al. (28) provided normal limits for
tress-induced changes in LV function and volumes using
ated 82rubidium PET in women. Quantitative blood flow
sing 13N-ammonia and 15O-labeled water PET in an
nimal model of acute infarction revealed that both ap-
roaches compared closely with blood flow assessed using
icrospheres (29). Alexanderson et al. (30) used 13N-
mmonia PET to demonstrate endothelial dysfunction in
atients with primary hypercholesterolemia. Free fatty acid
etabolism can be studied with using 11C-palmitate and
ET, and Ukkonen et al. (31) showed that an acute
eduction in availability of free fatty acids (used for aerobic
etabolism) resulted in a decrease in LV systolic function
nd myocardial efficiency in heart failure patients. This was
n unexpected finding, because it generally was believed
hat, in the failing heart, the absence of free fatty acids
esults in a switch to cardiac glucose metabolism, which is
ssociated with superior cardiac efficiency.
In another PET study with FDG, it was demonstrated
hat hyperinsulinemic euglycemic clamping maximally stim-
lated regional glucose utilization, both in patients with and
ithout diabetes and reduced LV function, although greater
egional glucose utilization was noted in patients with
ormal LV function (32).
onclusions
hese Scientific Sessions demonstrated the continued im-
ortant clinical role of nuclear cardiology, in the evaluation,
anagement, and determination of treatment strategies for
atients with cardiovascular disease. In addition, nuclear
ardiology studies provide insight with regard to the evalu-
tion of the pathophysiological processes of cardiovascular
isease. Renewed emphasis was placed on the use of
adionuclides to better understand molecular processes
hile also demonstrating the important clinical role that
PECT and PET imaging plays in routine clinical practice.
ith a continued attendance of more than 1,000 specialists
n nuclear cardiology, these Annual Sessions continue to
enerate worldwide interest. Next year’s meeting will be
eld in San Diego, California, from September 6 to 9, 2007.
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